Clinical-stage cancer drug developer using stabilized helical peptides (Helicons) to reach hard targets inside cells; lead drug zolucatetide blocks beta-catenin.
Clinical-stage cancer drug developer using stabilized helical peptides (Helicons) to reach hard targets inside cells; lead drug zolucatetide blocks beta-catenin.
With no approved product, it is funded by investor money and partner payments, chiefly a May 2026 deal with Regeneron on antibody-Helicon conjugates, antibodies that carry a Helicon in place of a toxic payload, with upfront and milestone fees. It listed on Nasdaq in June 2026. Value rests on zolucatetide's desmoid-tumor results.
Moat: narrow (IP / patents, process know-how). Proprietary Helicon peptide platform; only one drug in the clinic so far, so the edge is unproven.
Headquarters: Cambridge, Massachusetts, US · Founded: 2015
Size Parabilis Medicines (PBLS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.52B, the 1425th largest of 3,085 United States companies the cockpit tracks. Shares closed at $28.47 on 18 Nov 2026.
Capital Return on invested capital runs 88.7 points below its cost of capital (19.9% WACC).
Short interest Short interest is 9.1% of the free float (30 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $0 | $0 |
| Revenue growth | — | — | — |
| Gross profit | n/a | -$2.50M | -$2.11M |
| EBITDA | n/a | -$150M | -$124M |
| Net income | n/a | -$146M | -$118M |
| Free cash flow | n/a | -$124M | -$105M |
| Capital expenditure | n/a | $306,000 | $879,000 |
| Total debt | $41.8M | $58.7M | $66.2M |
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Parabilis Medicines PBLS | $3.52B | n/a | n/a | n/a | n/a | n/a |
| Arvinas ARVN | $443M | -26% | -12% | -10% | n/a | n/a |
| Kymera Therapeutics KYMR | $10.3B | +50% | +134% | -396% | 92.4× | n/a |
| Revolution Medicines RVMD | $34.6B | +6% | n/a | -853% | 162.6× | n/a |
| Merck KGaA MRK.DE | $71.3B | +16% | +1% | 19% | 3.4× | 7.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PBLS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.1% | +2.6% | 9th highest of 21 |
| Distance from 52-week high | -33.0% | -21.3% | 5th lowest of 21 |
| ROIC minus cost of capital | -88.7 pp | +4.3 pp | 2nd lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 2.8× | n/a | n/a |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | 9.3× | 58.0% | +4.2% |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 20.4× | n/a | n/a |
| Shanghai Junshi Biosciences 1877.HK | Hong Kong | $3.49B | -38% | +36% | -14% | 8.4× | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 6.6× | 49.2% | +367.3% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 3.1× | -2.1% | +12.0% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 0.6× | -4.9% | +7.8% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 3.2× | 6.4% | +5.9% |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | 106.6× | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 2.6× | -3.4% | +10.6% |
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 3.8× | n/a | n/a |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 1.8× | -4.1% | -1.0% |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 2.5× | 4.7% | +4.5% |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.73B | -9% | -10% | 19% | 2.3× | -7.0% | +2.0% |
| Tarsus Pharmaceuticals TARS | United States | $3.74B | +17% | +86% | -10% | 5.2× | 34.7% | +159.5% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.75B | +12% | +14% | 20% | 4.2× | 1.2% | +12.1% |